Samjin Pharmaceutical Co's basic earnings per share (Basic EPS) for the
three
months ended in Mar. 2026 was ₩110.00.
Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Mar. 2026 was ₩1,770.00.
Samjin Pharmaceutical Co's EPS without NRI for the
three
months ended in Mar. 2026 was ₩130.78.
Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Mar. 2026 was 1,758.67.
During the past 12 months, Samjin Pharmaceutical Co's average EPS without NRIGrowth Rate was -46.30% per year.
During the past 3 years, the average EPS without NRIGrowth Rate was 9.00% per year.
During the past 5 years, the average EPS without NRIGrowth Rate was 1.20% per year.
During the past 10 years, the average EPS without NRIGrowth Rate was -1.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.
During the past 13 years, Samjin Pharmaceutical Co's highest 3-Year average EPS without NRI Growth Rate was 60.50% per year. The lowest was -27.70% per year. And the median was 11.05% per year.
Samjin Pharmaceutical Co (XKRX:005500) EPS (Basic) Explanation
EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.
Be Aware
Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.
If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.
Samjin Pharmaceutical Co EPS (Basic) Related Terms
Samjin Pharmaceutical Co EPS (Basic) Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.
Samjin Pharmaceutical Co's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as
EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩1,770.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Samjin Pharmaceutical Co (XKRX:005500) has a EPS (Basic) of ₩1,770.00 as of Mar. 2026. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Samjin Pharmaceutical Co and its competitors.
Is Samjin Pharmaceutical Co's EPS (Basic) too high?
Samjin Pharmaceutical Co's current EPS (Basic) is ₩1,770.00. Overall, Samjin Pharmaceutical Co has a GF Score™ of 89/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Samjin Pharmaceutical Co's EPS (Basic) compare to ZTS?
Samjin Pharmaceutical Co's EPS (Basic) of ₩1,770.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Drug Manufacturers company?
A good EPS (Basic) depends on the Drug Manufacturers industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Samjin Pharmaceutical Co and its competitors. Samjin Pharmaceutical Co's current EPS (Basic) is ₩1,770.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Samjin Pharmaceutical Co stock overvalued right now?
Based on GuruFocus' analysis, Samjin Pharmaceutical Co (XKRX:005500) is currently considered Fairly Valued. The stock's GF Value™ is ₩19,985.91, compared to a current price of ₩18,350.00 — trading 8.2% below its estimated fair value. The current EPS (Basic) is ₩1,770.00. Samjin Pharmaceutical Co's overall GF Score™ is 89/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Samjin Pharmaceutical Co (XKRX:005500), the current EPS (Basic) is ₩1,770.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Samjin Pharmaceutical Co (XKRX:005500) Overvalued in 2026?
Based on GuruFocus' analysis, Samjin Pharmaceutical Co stock appears to be undervalued.
The current stock price of ₩18,350.00 is trading 8.2% below its estimated GF Value™ of ₩19,985.91.
GuruFocus considers Samjin Pharmaceutical Co to be Fairly Valued.
Key valuation signals for XKRX:005500:
EPS (Basic): ₩1,770.00
GF Value™: ₩19,985.91 vs. price of ₩18,350.00 (8.2% below fair value)
No single metric tells the full story. See the XKRX:005500 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Samjin Pharmaceutical Co Ltd is a part of the healthcare sector in Korea. The company functions as a pharmaceutical product manufacturer addressing severe diseases such as osteoporosis, hepatitis, respiratory and gastrointestinal diseases. Its suite of products includes capsules, syringes, injection medicines, and solvents.
89GF Score
Get the complete analysis for XKRX:005500
EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XKRX:005500 has been successfully added to your 
